- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 12:25 | SKB BIO (06990): DISCLOSEABLE TRANSACTION SUBSCRIPTIONS FOR WEALTH MANAGEMENT PRODUCTS | - | HKEx | ||
| Mo | G Sachs Raises SKB BIO TP to HKD561.4, Rating Buy | 2 | AASTOCKS | ||
| So | Kelun-Biotech: Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC Published in The Lancet | 403 | PR Newswire | CHENGDU, China, May 30, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that the results of the Phase III clinical study... ► Artikel lesen | |
| SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL Aktie jetzt für 0€ handeln | |||||
| Sa | Kelun-Biotech: The Results of Phase III OptiTROP-Lung05 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ASCO Oral Presentation and Simultaneously Published in The Lancet | 726 | PR Newswire | CHENGDU, China, May 29, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company", 6990.HK) announced today that at the 2026 American Society of Clinical Oncology... ► Artikel lesen | |
| 26.05. | Nomura Raises SKB BIO TP to HKD544.42; Encouraging Lung Cancer Data | 1 | AASTOCKS | ||
| 25.05. | SKB BIO (06990): GRANT OF RSUS UNDER THE 2025 SHARE INCENTIVE SCHEME AND PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION | 1 | HKEx | ||
| 22.05. | Merck and Kelun's lung cancer combo bests Keytruda in late-stage trial | 10 | Seeking Alpha | ||
| 22.05. | SKB BIO to Present Multiple Innovative Drug Research Results at ASCO Annual Meeting in US | 1 | AASTOCKS | ||
| 22.05. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT RESULTS FROM MULTIPLE STUDIES OF INNOVATIVE DRUGS AT 2026 ASCO ANNUAL MEETING | 1 | HKEx | ||
| 21.05. | ASCO: Merck, Kelun's sac-TMT ADC combo beats Keytruda by 65% on progression in first-line lung cancer | 19 | FiercePharma | ||
| 18.05. | Merck, Kelun score with sac-TMT in endometrial cancer trial | 4 | FiercePharma | ||
| 13.05. | SKB BIO (06990.HK) SKB118 New Drug IND Application Approved in Mainland China | 1 | AASTOCKS | ||
| 13.05. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT INVESTIGATIONAL NEW DRUG APPROVAL FOR SKB118 BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | 1 | HKEx | ||
| 12.05. | JPM: NRDL Adjustment to Accelerate Commercialization of Innovative Drugs; Top Picks INNOVENT BIO , WUXI APPTEC , WUXI XDC , SKB BIO | 3 | AASTOCKS | ||
| 08.05. | Kelun-Biotech: The sNDA for Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-positive NSCLC Accepted for Review by NMPA | 142 | PR Newswire | CHENGDU, China, May 8, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") announced that the sNDA (the "Application")... ► Artikel lesen | |
| 08.05. | SKB BIO (06990): VOLUNTARY ANNOUNCEMENT NEW INDICATION APPLICATION FOR CORE PRODUCT TROP2 ADC SACITUZUMAB TIRUMOTECAN (SAC-TMT) ACCEPTED BY THE NATIONAL ... | - | HKEx | ||
| 29.04. | Sichuan Kelun Pharmaceutical Co., Ltd. Announces Drop In Q1 Bottom Line | 3 | RTTNews | ||
| 17.04. | SKB BIO (06990): ARTICLES OF ASSOCIATION | - | HKEx | ||
| 17.04. | SKB BIO (06990): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 17.04. | SKB BIO (06990): INSIDE INFORMATION COMPLETION OF THE H SHARE FULL CIRCULATION BY THE COMPANY | - | HKEx |
1 2 3 4 Weiter >>
63 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 30,975 | +0,88 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat die Einstufung für Qiagen mit einem Kursziel von 43 US-Dollar auf "Buy" belassen. Das Interesse der Investoren habe vor allem dem Tuberkulosetest... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 25,110 | -12,96 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Repurchase of Royalty Obligations in Tanabe License Agreement and Concurrent Financing | - Repurchase of lorundrostat royalty obligation in Tanabe license agreement for $200 million upfront and up to $100 million once certain commercial milestones are met - - $500 million committed... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 272,33 | +5,52 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Provides Vormatrigine Program Update | POWER1 Study in highly refractory patients with focal onset seizures did not meet its primary success measure Secondary measure, the 50% response rate, was met and seizure reduction during the second... ► Artikel lesen | |
| ERASCA | 13,000 | -3,56 % | Erasca, Inc.: Erasca Reports First Quarter 2026 Business Updates and Financial Results | Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted... ► Artikel lesen | |
| COGENT BIOSCIENCES | 32,050 | -2,17 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) ... | Bezuclastinib combination is first treatment ever to demonstrate statistically significant advantage against active comparator in GIST patients; median PFS of 16.5 months versus 9.2 months (HR=0.50... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 14,930 | +0,47 % | Cantor Fitzgerald reiterates Overweight on Summit Therapeutics stock | ||
| ABIVAX | 75,60 | +19,24 % | Abivax mit Daten: Erst Rakete, dann Absturz - erhöht Obefazimod das Krebsrisiko? | Die Aktie von Abivax hat am Montagabend genau die Nachricht geliefert, auf die Investoren seit Monaten gewartet hatten. Das französische Biotech-Unternehmen präsentierte herausragende Topline-Ergebnisse... ► Artikel lesen | |
| VERA THERAPEUTICS | 30,760 | -1,52 % | Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy | Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)Revised ORIGIN 3 eGFR... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 81,92 | +4,08 % | Weekly Buzz: AstraZeneca, JNJ Get FDA Nod; Eli Lilly To Acquire Curevo; APGE Advances Zumilokibart | NEW BRUNSWICK (dpa-AFX) - This week in the biotech space, there were regulatory approvals across the U.S. and Europe, collaborations, acquisitions, and positive data readouts spanning multiple... ► Artikel lesen | |
| EVOTEC | 5,025 | -1,37 % | EQS-NVR: Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Gesamtstimmrechtsmitteilung: Evotec SE
/ Veröffentlichung der Gesamtzahl der Stimmrechte
Evotec SE: Veröffentlichung der Gesamtzahl der Stimmrechte nach § 41 WpHG mit dem... ► Artikel lesen | |
| RELAY THERAPEUTICS | 15,140 | -3,57 % | Relay Therapeutics Shares Jump 18% | ||
| KYMERA THERAPEUTICS | 72,37 | +1,51 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,440 | -4,71 % | Recursion Pharmaceuticals: Recursion Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules | ||
| EDGEWISE THERAPEUTICS | 36,650 | -1,61 % | Servier to Acquire Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology for patients with high unmet medical needs.Transaction includes sevasemten, a late-stage investigational treatment for... ► Artikel lesen | |
| BIONTECH | 76,20 | -0,13 % | UBS stuft Biontech auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Biontech von "Neutral" auf "Buy" hochgestuft und das Kursziel von 117 auf 135 US-Dollar angehoben. David Dai begründete die Kaufempfehlung... ► Artikel lesen |
Das Unternehmen SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD kann der Branche Biotechnologie zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO LTD finden Sie auf Wallstreet Online.